Navigation Links
National Personal Injury Lawyers, TorHoerman Law, Provides Yaz Lawsuit Update
Date:7/31/2012

CHICAGO, July 31, 2012 /PRNewswire/ -- The one-time poster child of birth control prescriptions, Yaz (and Yasmin) has quickly become one of the riskiest oral contraceptives available.

Released in 2006, the contraceptive Yaz generated sales of nearly $2 billion in its first year alone, making it the one time leading birth control pill on the market and Bayer HealthCare Pharmaceutical's top-selling drug.

But in 2012, Bayer is facing over 15,000 lawsuits involving this same blockbuster drug.

Promoted as the choice for women seeking relief from premenstrual symptoms and acne, Yaz's marketing touted the birth control pill as one with multiple benefits. "Yaz is the only birth control pill proven to treat the physical and emotional premenstrual symptoms that are severe enough to impact your life," claimed many of the advertisements; advertising statements that have since been removed.

Instead, recent studies have shown that this marketing was not only misleading but also dangerous. These independent studies have found that Yaz carries higher blood clotting risks than other leading birth control pills.

The attorneys at TorHoerman Law are actively representing women affected by the life-altering side effects of Yaz and Yasmin. The most common injuries involve women who have suffered stroke, Deep Vein Thrombosis (DVT) or Pulmonary Embolism after taking Yaz or Yasmin.

In their second quarter financial statements, Bayer announced that agreements had been reached to settle the claims of 1,877 claimants in the U.S. for a total amount of about $402.6 million. These numbers increased since the first quarter, when Bayer announced they had settled the claims of 651 plaintiffs in the U.S. for a total amount of about $142 million.

TorHoerman Law urges any women that experienced any of these side effects to contact an experienced attorney soon to investigate whether you have a right to compensation for your injuries. http://www.torhoermanlaw.com

 


'/>"/>
SOURCE TorHoerman Law
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
2. Austen BioInnovation Institute in Akron Attracts Nationally Known Speakers For Conference on Value-driven Engineering, April 23-24
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
6. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
7. Fuse Science Partners With GNC To Open National Distribution Of EnerJel™
8. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
9. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
10. WAISMANN METHOD® Director Encourages Public to Participate in National Take-Back Day
11. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy ... the preferred physical therapy provider for Derby City CrossFit, effective immediately. , In ... as quickly and effectively as possible, ProRehab’s sports physical therapists will work with ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... Liberty attempts to compare student test score performance for the 2015-16 school year ... the state’s voucher programs. Though it highlights important patterns in student test score ...
(Date:4/25/2017)... ... 2017 , ... As pharmaceutical companies are held to increasingly ... innovation in drug formulation and manufacturing. CoreRx offers its clients more than ... support of their development and manufacturing goals. , The company was created ...
(Date:4/25/2017)... ... , ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care ... on preventative care with all my patients to alleviate possible future issues. I am pleased ... contact my office and my trained staff will assist you in any way possible.” , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):